ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
ImmunityBio (NASDAQ: IBRX) and nCartes have entered a collaboration agreement to automate and streamline clinical trial data fulfillment processes. The partnership aims to replace manual data entry into Electronic Data Capture (EDC) systems with direct digital information transfer from electronic medical record (EMR) systems. This automation initiative is designed to make the process faster, more cost-effective, and reduce potential errors in data entry. The collaboration seeks to improve data quality and reduce the time required for source data verification, potentially accelerating the timeline for bringing therapies to market.
ImmunityBio (NASDAQ: IBRX) e nCartes hanno siglato un accordo di collaborazione per automatizzare e semplificare i processi di raccolta dei dati nelle sperimentazioni cliniche. L'obiettivo della partnership è quello di sostituire l'immissione manuale dei dati nei sistemi di acquisizione elettronica dei dati (EDC) con un trasferimento diretto delle informazioni digitali dai sistemi di cartelle cliniche elettroniche (EMR). Questa iniziativa di automazione è progettata per rendere il processo più veloce, più economico e per ridurre i potenziali errori nell'inserimento dei dati. La collaborazione mira a migliorare la qualità dei dati e a ridurre i tempi necessari per la verifica dei dati sorgente, accelerando potenzialmente il processo di immissione sul mercato delle terapie.
ImmunityBio (NASDAQ: IBRX) y nCartes han firmado un acuerdo de colaboración para automatizar y simplificar los procesos de recopilación de datos en ensayos clínicos. El objetivo de la asociación es reemplazar la entrada manual de datos en los sistemas de Captura Electrónica de Datos (EDC) con una transferencia directa de información digital desde los sistemas de registros médicos electrónicos (EMR). Esta iniciativa de automatización está diseñada para hacer el proceso más rápido, más rentable y reducir posibles errores en la entrada de datos. La colaboración busca mejorar la calidad de los datos y reducir el tiempo requerido para la verificación de datos fuente, acelerando potencialmente el cronograma para llevar terapias al mercado.
ImmunityBio (NASDAQ: IBRX)와 nCartes는 임상 시험 데이터 이행 프로세스를 자동화하고 간소화하기 위한 협력 계약을 체결했습니다. 이 파트너십은 전자 의료 기록(EMR) 시스템에서 전자 데이터 캡처(EDC) 시스템으로의 수동 데이터 입력을 디지털 정보 전송으로 대체하는 것을 목표로 합니다. 이 자동화 이니셔티브는 프로세스를 더 빠르고 비용 효율적으로 만들고 데이터 입력의 잠재적 오류를 줄이기 위해 설계되었습니다. 이 협력은 데이터 품질을 개선하고 출처 데이터 검증에 소요되는 시간을 단축하여 치료제의 시장 출시 일정을 가속화할 수 있습니다.
ImmunityBio (NASDAQ: IBRX) et nCartes ont conclu un accord de collaboration pour automatiser et rationaliser les processus de collecte des données des essais cliniques. L'objectif de ce partenariat est de remplacer la saisie manuelle des données dans les systèmes de capture électronique des données (EDC) par un transfert direct d'informations numériques depuis les systèmes de dossiers médicaux électroniques (EMR). Cette initiative d'automatisation est conçue pour rendre le processus plus rapide, plus rentable et réduire les erreurs potentielles de saisie des données. La collaboration vise à améliorer la qualité des données et à réduire le temps nécessaire à la vérification des données sources, ce qui pourrait accélérer le calendrier de mise sur le marché des thérapies.
ImmunityBio (NASDAQ: IBRX) und nCartes haben eine Vereinbarung zur Zusammenarbeit getroffen, um die Prozesse zur Erfüllung von klinischen Studien zu automatisieren und zu optimieren. Ziel der Partnerschaft ist es, die manuelle Dateneingabe in elektronische Datenerfassungssysteme (EDC) durch den direkten digitalen Informationsaustausch aus elektronischen Patientenakten (EMR) zu ersetzen. Diese Automatisierungsinitiative ist darauf ausgelegt, den Prozess schneller, kostengünstiger zu gestalten und potenzielle Fehler bei der Dateneingabe zu reduzieren. Die Zusammenarbeit zielt darauf ab, die Datenqualität zu verbessern und die erforderliche Zeit für die Überprüfung der Quelldaten zu reduzieren, wodurch der Zeitrahmen für die Markteinführung von Therapien potenziell beschleunigt wird.
- Implementation of automated data collection system to reduce costs
- Potential reduction in clinical trial timeline delays
- Expected improvement in data quality through reduced manual entry errors
- None.
Insights
This collaboration with nCartes represents an operational efficiency improvement in clinical trial data management, but its immediate financial impact is While automating data collection could potentially accelerate trial timelines and reduce costs, the benefits will materialize gradually across ImmunityBio's trial portfolio. The shift from manual to automated EMR-to-EDC data transfer addresses a significant pain point in clinical research, potentially reducing errors and speeding up data verification.
The key value proposition lies in the potential to accelerate time-to-market for ImmunityBio's therapies by streamlining data collection and verification. However, this represents an incremental operational improvement rather than a transformative catalyst. The partnership may yield modest cost savings in data entry and verification, but these are likely to be relatively small compared to overall trial costs.
The vast majority of clinical trials today gather data manually at clinical research sites. The data is then entered by hand into Electronic Data Capture (EDC) systems used by clinical trial sponsors. This process is time-consuming, costly, and creates the potential for errors that can further delay trial results. This new collaboration will instead rely on using digital information available in source electronic medical record (EMR) systems to directly populate EDC systems.
"ImmunityBio's innovations in immunotherapies for cancer and infectious diseases depend on getting timely and accurate data from our many ongoing clinical trials," said Richard Adcock, President and CEO of ImmunityBio. "The EMR-to-EDC capability nCartes provides will transform this process, reducing delays and enabling us to potentially bring important therapies to market faster."
Automating the process also will help to reduce data entry mistakes and thereby improves data quality, which also materially reduces the cost and elapsed time required for source data verification.
"ImmunityBio is doing incredible work with its novel immune system-based therapeutics and vaccines, and has an aggressive clinical trial program," said John S. McIlwain, CEO of nCartes. "The nCartes team is honored to have this opportunity to work alongside the ImmunityBio team and their research sites to potentially materially improve the crucial data collection aspect of those trials."
About nCartes
nCartes (https://ncartes.ncoup.com) is a transformational cloud software platform provider. The nCartes platform enables clinical research sponsors and research sites to harness electronic health systems (EHRs) to automate data capture for clinical trials, patient registries, cell manufacturing and more.
Contact: info@nCoup.com
LinkedIn: www.linkedin.com/company/ncartes-inc
About ImmunityBio
ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit www.immunitybio.com and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunitybio-and-ncartes-enter-collaboration-agreement-on-clinical-trial-data-fulfillment-302312171.html
SOURCE nCoup, Inc.
FAQ
What is the purpose of ImmunityBio's collaboration with nCartes announced in November 2024?
How will the IBRX-nCartes collaboration improve clinical trial efficiency?
What technology will ImmunityBio (IBRX) implement for clinical trial data management?
